Literature DB >> 32781488

Dismantling the Fragility Index: A demonstration of statistical reasoning.

Gail E Potter1.   

Abstract

The Fragility Index has been introduced as a complement to the P-value to summarize the statistical strength of evidence for a trial's result. The Fragility Index (FI) is defined in trials with two equal treatment group sizes, with a dichotomous or time-to-event outcome, and is calculated as the minimum number of conversions from nonevent to event in the treatment group needed to shift the P-value from Fisher's exact test over the .05 threshold. As the index lacks a well-defined probability motivation, its interpretation is challenging for consumers. We clarify what the FI may be capturing by separately considering two scenarios: (a) what the FI is capturing mathematically when the probability model is correct and (b) how well the FI captures violations of probability model assumptions. By calculating the posterior probability of a treatment effect, we show that when the probability model is correct, the FI inappropriately penalizes small trials for using fewer events than larger trials to achieve the same significance level. The analysis shows that for experiments conducted without bias, the FI promotes an incorrect intuition of probability, which has not been noted elsewhere and must be dispelled. We illustrate shortcomings of the FI's ability to quantify departures from model assumptions and contextualize the FI concept within current debate around the null hypothesis significance testing paradigm. Altogether, the FI creates more confusion than it resolves and does not promote statistical thinking. We recommend against its use. Instead, sensitivity analyses are recommended to quantify and communicate robustness of trial results.
© 2020 John Wiley & Sons, Ltd.

Keywords:  P-value; Bayes factor; Fragility Index; robustness; sensitivity analysis

Mesh:

Year:  2020        PMID: 32781488     DOI: 10.1002/sim.8689

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  The fragility index can be used for sample size calculations in clinical trials.

Authors:  Benjamin R Baer; Mario Gaudino; Stephen E Fremes; Mary Charlson; Martin T Wells
Journal:  J Clin Epidemiol       Date:  2021-08-15       Impact factor: 6.437

2.  Fragility indices for only sufficiently likely modifications.

Authors:  Benjamin R Baer; Mario Gaudino; Mary Charlson; Stephen E Fremes; Martin T Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-07       Impact factor: 12.779

Review 3.  Outcome of acute kidney injury: how to make a difference?

Authors:  Matthieu Jamme; Matthieu Legrand; Guillaume Geri
Journal:  Ann Intensive Care       Date:  2021-04-15       Impact factor: 6.925

4.  Meta-analyses in paediatric surgery are often fragile: implications and consequences.

Authors:  Arne Schröder; Oliver J Muensterer; Christina Oetzmann von Sochaczewski
Journal:  Pediatr Surg Int       Date:  2021-01-16       Impact factor: 1.827

5.  On clinical trial fragility due to patients lost to follow up.

Authors:  Benjamin R Baer; Stephen E Fremes; Mario Gaudino; Mary Charlson; Martin T Wells
Journal:  BMC Med Res Methodol       Date:  2021-11-20       Impact factor: 4.615

6.  Paediatric surgical trials, their fragility index, and why to avoid using it to evaluate results.

Authors:  Arne Schröder; Oliver J Muensterer; Christina Oetzmann von Sochaczewski
Journal:  Pediatr Surg Int       Date:  2022-05-07       Impact factor: 2.003

7.  The Fragility Index for Assessing the Robustness of the Statistically Significant Results of Experimental Clinical Studies.

Authors:  Adrienne K Ho
Journal:  J Gen Intern Med       Date:  2021-08-06       Impact factor: 5.128

8.  The fragility index may not be ideal for paediatric surgical conditions: the example of foetal endoscopic tracheal occlusion.

Authors:  Arne Schröder; Oliver J Muensterer; Christina Oetzmann von Sochaczewski
Journal:  Pediatr Surg Int       Date:  2021-05-29       Impact factor: 1.827

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.